Dow Jones Newswires 
(1/27, FitzGerald, Subscription Publication) reports that the US Court
of Appeals for the Federal Circuit has stayed a decision that blocked
Watson Pharmaceuticals Inc. from selling its generic blood thinner. The
court's decision postponed an injunction issued in October that had
prevented Watson and partner Amphastar Pharmaceuticals Inc. from selling
their version of Lovenox [enoxaparin], a blood thinner from Sanofi.
Amphastar's abbreviated drug
application for enoxaparin sodium was approved by the Food and Drug
Administration.
No comments:
Post a Comment